INCB123667 + ribociclib + fulvestrant

This is a combination investigational regimen consisting of **INCB123667** (an investigational selective cyclin-dependent kinase 2 [CDK2] inhibitor developed by Incyte), **ribociclib** (a marketed CDK4/6 inhibitor developed by Novartis, brand name Kisqali), and **fulvestrant** (an estrogen receptor antagonist marketed as Faslodex by AstraZeneca). INCB123667 is being studied to overcome resistance mechanisms to standard CDK4/6 and endocrine therapy, particularly in hormone receptor-positive (HR+), HER2-negative advanced or metastatic breast cancer and other solid tumors. Combination therapy aims to achieve synergistic anti-tumor effects by dual targeting of the cell cycle (CDK2 and CDK4/6 inhibition) and hormone receptor signaling blockade[1][2][3].

Other names

ribociclibfulvestrant